(Q48874659)

English

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

double-blind clinical trial

1 reference

based on heuristic

inferred from title

author name string

Latin-American Puregon IVF Study Group

1

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

language of work or name

0 references

publication date

1 November 2001

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

Fertility and Sterility

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

76

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

5

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

950-956

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. CPMP Working Party on Efficacy of Medicinal Products

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

An 18-month survey of infertility treatment by in vitro fertilization, gamete and zygote intrafallopian transfer, and replacement of frozen-thawed embryos

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

A model for follicular selection and ovulation: lessons from superovulation

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902844-8

7 January 2021

Identifiers

10.1016/S0015-0282(01)02844-8

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/11704116

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48874659&oldid=2212610829"